Inhaled corticosteroid normalizes some but not all airway vascular remodeling in COPD.

Soltani, A; Walters, EH; Reid, DW; Shukla, SD; Nowrin, K; Ward, C; Muller, HK; Sohal, SS

Inhaled corticosteroid normalizes some but not all airway vascular remodeling in COPD.

Soltani, A Walters, EH Reid, DW Shukla, SD Nowrin, K Ward, C Muller, HK Sohal, SS

Permalink

Publisher:: DOVE MEDICAL PRESS LTD
Publication Type:: Journal Article
Citation:: Int J Chron Obstruct Pulmon Dis, 2016, 11, (1), pp. 2359-2367
Issue Date:: 2016

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (2.1 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Soltani, A
dc.contributor.author	Walters, EH
dc.contributor.author	Reid, DW
dc.contributor.author	Shukla, SD
dc.contributor.author	Nowrin, K
dc.contributor.author	Ward, C
dc.contributor.author	Muller, HK
dc.contributor.author	Sohal, SS
dc.date.accessioned	2022-08-16T22:20:02Z
dc.date.available	2022-08-16T22:20:02Z
dc.date.issued	2016
dc.identifier.citation	Int J Chron Obstruct Pulmon Dis, 2016, 11, (1), pp. 2359-2367
dc.identifier.issn	1176-9106
dc.identifier.issn	1178-2005
dc.identifier.uri	http://hdl.handle.net/10453/160392
dc.description.abstract	BACKGROUND: This study assessed the effects of inhaled corticosteroid (ICS) on airway vascular remodeling in chronic obstructive pulmonary disease (COPD). METHODS: Thirty-four subjects with mild-to-moderate COPD were randomly allocated 2:1 to ICS or placebo treatment in a double-blinded clinical trial over 6 months. Available tissue was compared before and after treatment for vessel density, and expression of VEGF, TGF-β1, and TGF-β1-related phosphorylated transcription factors p-SMAD 2/3. This clinical trial has been registered and allocated with the Australian New Zealand Clinical Trials Registry (ANZCTR) on 17/10/2012 with reference number ACTRN12612001111864. RESULTS: There were no significant baseline differences between treatment groups. With ICS, vessels and angiogenic factors did not change in hypervascular reticular basement membrane, but in the hypovascular lamina propria (LP), vessels increased and this had a proportionate effect on lung air trapping. There was modest evidence for a reduction in LP vessels staining for VEGF with ICS treatment, but a marked and significant reduction in p-SMAD 2/3 expression. CONCLUSION: Six-month high-dose ICS treatment had little effect on hypervascularity or angiogenic growth factors in the reticular basement membrane in COPD, but normalized hypovascularity in the LP, and this was physiologically relevant, though accompanied by a paradoxical reduction in growth factor expression.
dc.format	Electronic-eCollection
dc.language	eng
dc.publisher	DOVE MEDICAL PRESS LTD
dc.relation.ispartof	Int J Chron Obstruct Pulmon Dis
dc.relation.isbasedon	10.2147/COPD.S113176
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1102 Cardiorespiratory Medicine and Haematology
dc.subject.classification	Respiratory System
dc.subject.mesh	Administration, Inhalation
dc.subject.mesh	Adrenal Cortex Hormones
dc.subject.mesh	Adult
dc.subject.mesh	Aged
dc.subject.mesh	Anti-Inflammatory Agents
dc.subject.mesh	Australia
dc.subject.mesh	Bronchodilator Agents
dc.subject.mesh	Double-Blind Method
dc.subject.mesh	Female
dc.subject.mesh	Fluticasone
dc.subject.mesh	Humans
dc.subject.mesh	Lung
dc.subject.mesh	Male
dc.subject.mesh	Middle Aged
dc.subject.mesh	Phosphorylation
dc.subject.mesh	Pulmonary Disease, Chronic Obstructive
dc.subject.mesh	Smad2 Protein
dc.subject.mesh	Smad3 Protein
dc.subject.mesh	Time Factors
dc.subject.mesh	Transforming Growth Factor beta1
dc.subject.mesh	Treatment Outcome
dc.subject.mesh	Vascular Endothelial Growth Factor A
dc.subject.mesh	Vascular Remodeling
dc.subject.mesh	Lung
dc.subject.mesh	Humans
dc.subject.mesh	Pulmonary Disease, Chronic Obstructive
dc.subject.mesh	Adrenal Cortex Hormones
dc.subject.mesh	Vascular Endothelial Growth Factor A
dc.subject.mesh	Bronchodilator Agents
dc.subject.mesh	Anti-Inflammatory Agents
dc.subject.mesh	Treatment Outcome
dc.subject.mesh	Administration, Inhalation
dc.subject.mesh	Double-Blind Method
dc.subject.mesh	Phosphorylation
dc.subject.mesh	Time Factors
dc.subject.mesh	Adult
dc.subject.mesh	Aged
dc.subject.mesh	Middle Aged
dc.subject.mesh	Australia
dc.subject.mesh	Female
dc.subject.mesh	Male
dc.subject.mesh	Smad2 Protein
dc.subject.mesh	Smad3 Protein
dc.subject.mesh	Transforming Growth Factor beta1
dc.subject.mesh	Vascular Remodeling
dc.subject.mesh	Fluticasone
dc.title	Inhaled corticosteroid normalizes some but not all airway vascular remodeling in COPD.
dc.type	Journal Article
utslib.citation.volume	11
utslib.location.activity	New Zealand
utslib.for	1102 Cardiorespiratory Medicine and Haematology
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
utslib.copyright.status	open_access	*
dc.date.updated	2022-08-16T22:20:00Z
pubs.issue	1
pubs.publication-status	Published online
pubs.volume	11
utslib.citation.issue	1

Abstract:

BACKGROUND: This study assessed the effects of inhaled corticosteroid (ICS) on airway vascular remodeling in chronic obstructive pulmonary disease (COPD). METHODS: Thirty-four subjects with mild-to-moderate COPD were randomly allocated 2:1 to ICS or placebo treatment in a double-blinded clinical trial over 6 months. Available tissue was compared before and after treatment for vessel density, and expression of VEGF, TGF-β1, and TGF-β1-related phosphorylated transcription factors p-SMAD 2/3. This clinical trial has been registered and allocated with the Australian New Zealand Clinical Trials Registry (ANZCTR) on 17/10/2012 with reference number ACTRN12612001111864. RESULTS: There were no significant baseline differences between treatment groups. With ICS, vessels and angiogenic factors did not change in hypervascular reticular basement membrane, but in the hypovascular lamina propria (LP), vessels increased and this had a proportionate effect on lung air trapping. There was modest evidence for a reduction in LP vessels staining for VEGF with ICS treatment, but a marked and significant reduction in p-SMAD 2/3 expression. CONCLUSION: Six-month high-dose ICS treatment had little effect on hypervascularity or angiogenic growth factors in the reticular basement membrane in COPD, but normalized hypovascularity in the LP, and this was physiologically relevant, though accompanied by a paradoxical reduction in growth factor expression.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/160392